

The rise in demand for automated systems for glycemic control, the incidence of diabetes, and intense research and development activities by industry players are the key growth drivers. Patients with diabetes have their blood glucose levels controlled by an artificial pancreas device system, and industry players are doing several studies to better diabetes treatment. For instance, Medtronic introduced the MiniMed 670G, the first hybrid closed-loop device with the ability to self-adjust to maintain a healthy blood sugar level. Many other organisations are working to create a technologically sophisticated artificial pancreas device system.
Read More:
Click here for Artificial Pancreas Device System (APDS) Market Press Release:





